Epirubicin in breast cancer treatment

Detalhes bibliográficos
Autor(a) principal: Saad, Everardo D.
Data de Publicação: 2007
Outros Autores: Facina, Gil, Gebrim, Luiz Henrique
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/1829
Resumo: Epirubicin is a doxorubicin analog that is increasingly used in the management of patients with early and advanced breast cancer. Epirubicin is less cardiotoxic than doxorubicin, thus providing a convenient alternative to the parent compound. Studies in early and advanced breast cancer suggest that these two anthracyclines can be used interchangeably, although the exact dose equivalence between epirubicin and doxorubicin has not been determined. In adjuvant treatment, which aims at cure, studies reported thus far have been unable to establish the most active dose or the best combination containing epirubicin. This article provides an overview of randomized trials and meta-analyses that have attempted to define the role of epirubicin in curative and palliative chemotherapy for patients with breast cancer. Our main question concerns the ideal dose of epirubicin in adjuvant treatment, and we conclude by suggesting the chemotherapy regimen containing epirubicin that we consider most suitable.
id INCA-1_83b33b0cf367bb78215ee4d13adf0970
oai_identifier_str oai:rbc.inca.gov.br:article/1829
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Epirubicin in breast cancer treatmentEpirrubicina no tratamento do câncer de mamaAntibióticos antineoplásicosAntraciclinasDoxorrubicinaNeoplasias mamáriasQuimioterapiaAntibioticsAntineoplasticAnthracyclinesBreast cancerDoxorubicinChemotherapyEpirubicinEpirubicin is a doxorubicin analog that is increasingly used in the management of patients with early and advanced breast cancer. Epirubicin is less cardiotoxic than doxorubicin, thus providing a convenient alternative to the parent compound. Studies in early and advanced breast cancer suggest that these two anthracyclines can be used interchangeably, although the exact dose equivalence between epirubicin and doxorubicin has not been determined. In adjuvant treatment, which aims at cure, studies reported thus far have been unable to establish the most active dose or the best combination containing epirubicin. This article provides an overview of randomized trials and meta-analyses that have attempted to define the role of epirubicin in curative and palliative chemotherapy for patients with breast cancer. Our main question concerns the ideal dose of epirubicin in adjuvant treatment, and we conclude by suggesting the chemotherapy regimen containing epirubicin that we consider most suitable.A epirrubicina, um análogo estrutural da doxorrubicina, pode ser empregada nas várias fases do tratamento quimioterápico do câncer de mama. A epirrubicina possui a vantagem de causar menor toxicidade cardíaca do que a doxorrubicina, quando são comparadas doses habitualmente consideradas como semelhantes do ponto de vista de eficácia. Apesar disso, ainda não está completamente estabelecida a equivalência de dose entre as duas antraciclinas. Os estudos em doenças localizada ou metastática sugerem que ambas podem ser empregadas de maneira intercambiável. Nos tratamentos curativo, em especial a quimioterapia adjuvante, ainda não foi definida a melhor dose ou o melhor esquema contendo a epirrubicina. Neste artigo, faz-se uma revisão do papel da epirrubicina no tratamento curativo e paliativo do câncer de mama, com ênfase maior na questão da dose deste quimioterápico que deve ser empregada no tratamento adjuvante. Discutem-se os estudos randomizados e as metanálises disponíveis até o presente momento e sugere-se o regime quimioterápico, contendo a epirrubicina, que mais parece adequado ao tratamento.INCA2007-03-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRevisão de literaturaapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/182910.32635/2176-9745.RBC.2007v53n1.1829Revista Brasileira de Cancerologia; Vol. 53 No. 1 (2007): Jan./Feb./Mar.; 47-53Revista Brasileira de Cancerologia; Vol. 53 Núm. 1 (2007): ene./feb./mar.; 47-53Revista Brasileira de Cancerologia; v. 53 n. 1 (2007): jan./fev./mar.; 47-532176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/1829/1109Saad, Everardo D.Facina, GilGebrim, Luiz Henriqueinfo:eu-repo/semantics/openAccess2021-11-29T20:26:35Zoai:rbc.inca.gov.br:article/1829Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:26:35Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Epirubicin in breast cancer treatment
Epirrubicina no tratamento do câncer de mama
title Epirubicin in breast cancer treatment
spellingShingle Epirubicin in breast cancer treatment
Saad, Everardo D.
Antibióticos antineoplásicos
Antraciclinas
Doxorrubicina
Neoplasias mamárias
Quimioterapia
Antibiotics
Antineoplastic
Anthracyclines
Breast cancer
Doxorubicin
Chemotherapy
Epirubicin
title_short Epirubicin in breast cancer treatment
title_full Epirubicin in breast cancer treatment
title_fullStr Epirubicin in breast cancer treatment
title_full_unstemmed Epirubicin in breast cancer treatment
title_sort Epirubicin in breast cancer treatment
author Saad, Everardo D.
author_facet Saad, Everardo D.
Facina, Gil
Gebrim, Luiz Henrique
author_role author
author2 Facina, Gil
Gebrim, Luiz Henrique
author2_role author
author
dc.contributor.author.fl_str_mv Saad, Everardo D.
Facina, Gil
Gebrim, Luiz Henrique
dc.subject.por.fl_str_mv Antibióticos antineoplásicos
Antraciclinas
Doxorrubicina
Neoplasias mamárias
Quimioterapia
Antibiotics
Antineoplastic
Anthracyclines
Breast cancer
Doxorubicin
Chemotherapy
Epirubicin
topic Antibióticos antineoplásicos
Antraciclinas
Doxorrubicina
Neoplasias mamárias
Quimioterapia
Antibiotics
Antineoplastic
Anthracyclines
Breast cancer
Doxorubicin
Chemotherapy
Epirubicin
description Epirubicin is a doxorubicin analog that is increasingly used in the management of patients with early and advanced breast cancer. Epirubicin is less cardiotoxic than doxorubicin, thus providing a convenient alternative to the parent compound. Studies in early and advanced breast cancer suggest that these two anthracyclines can be used interchangeably, although the exact dose equivalence between epirubicin and doxorubicin has not been determined. In adjuvant treatment, which aims at cure, studies reported thus far have been unable to establish the most active dose or the best combination containing epirubicin. This article provides an overview of randomized trials and meta-analyses that have attempted to define the role of epirubicin in curative and palliative chemotherapy for patients with breast cancer. Our main question concerns the ideal dose of epirubicin in adjuvant treatment, and we conclude by suggesting the chemotherapy regimen containing epirubicin that we consider most suitable.
publishDate 2007
dc.date.none.fl_str_mv 2007-03-30
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Revisão de literatura
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/1829
10.32635/2176-9745.RBC.2007v53n1.1829
url https://rbc.inca.gov.br/index.php/revista/article/view/1829
identifier_str_mv 10.32635/2176-9745.RBC.2007v53n1.1829
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/1829/1109
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 53 No. 1 (2007): Jan./Feb./Mar.; 47-53
Revista Brasileira de Cancerologia; Vol. 53 Núm. 1 (2007): ene./feb./mar.; 47-53
Revista Brasileira de Cancerologia; v. 53 n. 1 (2007): jan./fev./mar.; 47-53
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042248164048896

Registros relacionados